Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species

• Published in: Journal of clinical tuberculosis and other mycobacterial diseases 2024-08, Vol.36, p.100464, Article 100464
• Main Authors: Kato, Yukari, Ihara, Hiroaki, Takei, Satomi, Nakamura, Ayako, Fujimoto, Yuichi, Handoh, Tetsuya, Kurokawa, Kana, Arai, Yuta, Shibayama, Kohei, Sumiyoshi, Issei, Ochi, Yusuke, Watanabe, Junko, Hoshi, Kazuaki, Misawa, Shigeki, Togo, Shinsaku, Naito, Toshio, Tabe, Yoko, Miida, Takashi, Takahashi, Kazuhisa
• Format: Article
• Language: English
• Subjects: Clarithromycin; Fractional inhibitory concentration index; Isepamicin; Mycobacterium abscessus; Sitafloxacin
• ISSN: 2405-5794; 2405-5794
• DOI: 10.1016/j.jctube.2024.100464

This study evaluated the antimicrobial potency of the combination of isepamicin (ISP) for Mycobacterium abscessus species (MABS). 34 clinical MABS strains were isolated from clinical samples. Of them, 11 (32.4 %) were M. abscessus subsp. abscessus (Mab), 22 (64.7 %) were M. abscessus subsp. massiliense (Mma), and one (2.9 %) was M. abscessus subsp. bolletii (Mbo). We compared susceptibility to sitafloxacin (STFX)-ISP and clarithromycin (CLR)-ISP combinations with those of the antimicrobial agents alone, and synergistic effects were observed in 41.2 % and 17.6 % when treated with STFX-ISP and CLR-ISP. By hierarchical cluster analysis, the isolates divided into treatment-sensitive and treatment-resistant groups. Non-Mma or rough colony isolates were significantly likely to belong to the treatment-sensitive group (p = 0.024, p